New molecules designed by AI are validated in mice

Insilico Medicine, a company using artificial intelligence (AI) for drug discovery, published a paper on Monday describing new machine learning techniques designed to substantially accelerate and improve the drug discovery process. The paper, which was published in Nature Biotechnology, is titled "Deep learning enables rapid identification of potent DDR1 kinase inhibitors." The findings describe a timed challenge where the new AI system called Generative Tensorial Reinforcement Learning (GENTRL) had to determine new molecules for drug discovery. The GENTRL program managed to design six novel inhibitors of DDR1, a kinase target implicated in fibrosis and other diseases, in 21 days. According to the research, four compounds were active in biochemical assays, and two were validated in cell-based assays.